Scottish Medicines Consortium

rivastigmine 4.6mg/24h and 9.5mg/24h transdermal patch (Exelon®)   No. (414/07)
Novartis Pharmaceuticals UK Limited

Product Update

5 October 2007 *(issued November 2007)*

The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

rivastigmine transdermal patch (Exelon®) is accepted for restricted use within NHS Scotland for symptomatic treatment of moderately severe Alzheimer's dementia only.

It should be used in accordance with guidance from NHS Quality Improvement Scotland on the application of the National Institute for Health and Clinical Excellence (NICE) technology appraisal number 111. Within this context it is suitable for patients in whom rivastigmine is an appropriate choice of acetylcholinesterase inhibitor and in whom a transdermal patch is an appropriate choice of formulation.

Overleaf is the detailed advice on this product.

Advice must be treated in strict confidence until published on the SMC website (www.scottishmedicines.org.uk) on 12 November 2007.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 6 November 2007.

Chairman,
Scottish Medicines Consortium